title: [Antiviral and immunomodulating activity of polyprenyl phosphates in viral infections].
abstract: Expressed antiviral activity of Fortepren (FP) and Gamapren (GP), polyprenyl phosphate (PPP)-contaning agents, was demonstrated in experiments on mice infected with the human herpes simplex virus, type 1 (HSV1) or the vernal encephalitis virus (VEV). Since both the viral infections are of great social significance, the PPP-containing agents should be considered prospective for the medical practice. The experimental data suggested that both the drugs considerably inhibited the VEV infectiousness in the susceptible cell culture. The quantity of protein E, the main immunogen of VEV, in the culture fluid of the VEV infected cells was shown to be markedly lowered under the effect of FP and GP. It was demonstrated for the first time that FP and GP significantly inhibited evolution of the VEV protein E in the cell culture J-96. The experiments with the infectious rhinotracheitis virus (IRTV) of the corned cattle revealed that FP and GP greatly retarded the HSV1 development in the susceptible cell culture. One of the mechanisms of the antiviral action of the PPP-containing agents was likely the effect on the evolution of the virus proteins in the cells. The impact of FP on production of some key cytokines (CT) was studied on mice with experimental vernal encephalitis (IFN-gamma, IL-4 and IL-12). The content of the above mentioned CT in blood of the mice was determined by the IFA test. Under the normal conditions and in the mice infected with VEV, production of IL-12 and IFN-gamma was shown to be stimulated during the first 3-5 days after the FP administration, whereas in the animals not exposed to FP there was observed stimulation of the IL-4 production during the first 3 days after the contamination, followed by increased production of IL-12 and IFN-gamma.
authors.forename: A N
authors.initials: AN
authors.lastname: Vasil'ev
authors.forename: S V
authors.initials: SV
authors.lastname: Ozherelkov
authors.forename: v V
authors.initials: vV
authors.lastname: Kozlov
authors.forename: A V
authors.initials: AV
authors.lastname: Pronin
authors.forename: A V
authors.initials: AV
authors.lastname: Sanin
authors.forename: T M
authors.initials: TM
authors.lastname: Parfenova
authors.forename: A V
authors.initials: AV
authors.lastname: Izmest'eva
authors.forename: A M
authors.initials: AM
authors.lastname: Amchenkova
authors.forename: T N
authors.initials: TN
authors.lastname: Kozhevnikova
authors.forename: T N
authors.initials: TN
authors.lastname: Stepanova
authors.forename: A N
authors.initials: AN
authors.lastname: Narovlianskiĭ
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000494:pharmacology*; D002460:Cell Line; D006801:Humans; D007371:Interferon-gamma / Q000276:immunology*; D018664:Interleukin-12 / Q000276:immunology*; D015847:Interleukin-4 / Q000276:immunology*; D051379:Mice; D008807:Mice, Inbred BALB C; D011106:Polyisoprenyl Phosphates / Q000494:pharmacology*; D014777:Virus Diseases / Q000178:diet therapy / Q000276:immunology*
chemical_list: D000998:Antiviral Agents; C508598:IL4 protein, human; D011106:Polyisoprenyl Phosphates; D018664:Interleukin-12; D015847:Interleukin-4; D007371:Interferon-gamma